English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Purpose : The early BCR-ABL1 reduction had the prognostic impact of the chronic-phase chronic myeloid leukemia (CML-CP) patients. This study was to find a more precise early prognosis index at 3 months in the patients with newly diagnosed CML-CP, especially for the patients with BCR-ABL1 IS &gt;10%. Methods : We retrospectively analyzed the data of 79 newly diagnosed CML-CP patients from October 2013 to April 2017. All patients took imatinib regularly and continuously and monitored BCR-ABL1 transcript level at baseline and 3, 6, 9, 12, 18 months after starting imatinib treatment. Results : Among the 44(55.7%) patients with BCR/ABL1 IS ≤10% at 3 months after imatinib treatment, 12(27.3%) cases did not achieve major molecular response (MMR) at 12 months, and 7(14.9%) patients with the halving time BCR-ABL1 transcript ≤40 days failed to achieve MMR at 12 months. However, approximately twenty-six percent of the patients with BCR-ABL1 IS &gt;10% still obtained MMR. Moreover, the patients with BCR-ABL1 IS ≤10% and halving time ≤40 days had a significantly better MMR than that of the patients with the BCR-ABL1 IS ≤10% and halving time &gt;40 days (88.6% versus 11.1%, P &lt;0.001). However, the patients with the BCR-ABL1 IS &gt;10% and halving time &gt;40 days rarely achieved MMR at 12 months. Conclusion : These data indicated that the halving time of BCR-ABL1 transcript was also an important prognostic factor as that of the BCR-ABL1 IS . Combined observations of these two prognosis indexes are more accurate predictor for the long-term molecular response, especially for the CML-CP patients with BCR-ABL1 IS &gt;10%, and which is helpful for TKI switching as early as possible to improve patients' survival and reduce drug costs.

journal of cancer

BCR-ABL1 transcript decline ratio combined BCR-ABL1<sup>IS</sup> as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

BCR-ABL1 transcript decline ratio combined BCR-ABL1IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia

BCR-ABL1 transcript decline ratio combined BCR-ABL1^IS as a precise predictor for imatinib response and outcome in the patients with chronic myeloid leukemia